Eli Lilly is wagering up to $2.25 billion that artificial intelligence can design the next generation of genetic medicines, striking a deal with AI startup Profluent Bio that represents one of the pharmaceutical industry's largest bets on machine learning-designed therapeutics.
The partnership, announced Monday, will use Profluent's AI platform to design gene editors and genetic medicines for multiple disease targets. Lilly will pay $85 million upfront, with the remainder contingent on development milestones and commercial success.
The deal structure reveals Big Pharma's growing confidence in AI drug discovery. The $2.25 billion total value exceeds many traditional biotech acquisitions and signals that AI-designed drugs have moved from theoretical promise to commercial reality.
Profluent's technology uses large language models—similar to those powering ChatGPT—to design proteins that can edit genes or deliver genetic payloads. The platform has already generated thousands of novel gene editors that don't exist in nature, offering potential advantages over existing CRISPR-based tools.
Here's what makes this deal significant: Traditional gene therapy development is expensive and slow, often taking a decade and billions in investment. Profluent claims its AI can design candidates in months, dramatically compressing timelines and reducing costs. If the technology delivers, it could transform genetic medicine economics.
Lilly's interest focuses on metabolic diseases and neurodegenerative conditions, therapeutic areas where gene editing shows promise but faces technical challenges. The company has struggled to develop genetic medicines internally, making the external partnership strategically necessary.
The deal follows a pattern of increasing pharma investment in AI drug design. Roche paid $3 billion for Recursion Pharmaceuticals last year. AstraZeneca partnered with BenevolentAI in a deal worth up to $1.5 billion. Merck established a similar collaboration with Exscientia valued at .
